Cronus onus: Zeus heart phase III bust rumbles beyond Novo

Source Summary

Bad news from the Novo Nordisk A/S phase III trial called Zeus with IL-6 inhibitor ziltivekimab struck a blow to some drug developers’ theory about heart disease – and to their stocks. An update on the Zeus trial weighing the safety and efficacy of monoclonal antibody ziltivekimab nicked shares of Bagsvaerd, Denmark-based Novo (NYSE:NVO), which closed July 31 at $47.08, down $4.54.